Simeprevir once a day with peginterferon alfa-2a and ribavirin was well tolerated in HCV genotype 1-infected previous non-responders and was non-inferior to telaprevir , thus providing an alternative treatment in areas of the world where all-oral HCV regimens are not available or accessible .